Taiwan approves Medigen's COVID-19 vaccine candidate
Taiwan-based Medigen said last month it was seeking a speedy emergency use authorisation, or EUA, from the government for its vaccine candidate after safely completing Phase II trials.
The health ministry said in clinical trials in Taiwan the antibodies created by Medigen's vaccine candidate have been proven to be "no worse than" those created by AstraZeneca vaccines, and that there were no major safety concerns.
The ministry added that Medigen had to present a monthly report on safety for the vaccine candidate, MVC-COV1901, which is designed for people aged over 20, who will get two shots 28 days apart.
Health Minister Chen Shih-chung told reporters that with the EUA approved, it would now take some time for the company to ramp up its production. ■